Press Releases

// LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic Utrecht, The Netherlands and Philadelphia, USA – February 22, 2021 – LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in ... » Full Release
// LAVA Therapeutics to Present Corporate Overview at 39th Annual J.P. Morgan Healthcare Conference LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in gamma-delta T-cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:55 p.m. ET. » Full Release
// LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. The financing was co-led by new investors Novo Ventures, the venture arm of Novo Holdings, and Sanofi Ventures, and included additional new investors Redmile Group, LLC, Ysios Capital and BB Pureos Bioventures. In addition, current investors Versant, Gilde Healthcare and MRL Ventures Fund, LLC participated significantly in the round. » Full Release
// LAVA Therapeutics, Amsterdam UMC and Monash University Announce Publication of a Novel Cancer Immunotherapy Approach in Nature Cancer Utrecht, The Netherlands & Philadelphia, Sept 14, 2020-(BUSINESS WIRE)–LAVA Therapeutics B.V., a biotech company pioneering bispecific gamma-delta T cell engagers for cancer, Amsterdam UMC and the Monash Biomedicine Discovery Institute in Australia, today announced that Nature Cancer has published their co-authored paper titled, “A single domain bispecific antibody targeting CD1d and the NKT T cell receptor induces a potent antitumor response,” detailing a novel immune-oncology approach for the potential treatment of cancer. » Full Release
// Lava Therapeutics Appoints Oncology and Hematology Expert Benjamin Winograd, M.D., Ph.D., as Chief Medical Officer Utrecht, The Netherlands and Philadelphia, July 8, 2020 – Lava Therapeutics B.V., a biotech company pioneering bispecific gamma-delta T cell engagers for cancer, today announced the appointment of Benjamin Winograd, M.D., Ph.D., as the company’s chief medical officer. Dr. Winograd is a seasoned drug development expert with significant experience leading oncology and hematology programs within the pharmaceutical industry. In this new role, Dr. Winograd will report to Steve Hurly, chief executive officer, in their U.S. office, and oversee strategic direction of clinical operations, translational medicine and regulatory affairs.  » Full Release
// Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics Utrecht, The Netherlands and Philadelphia, May 15, 2020 – Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson & Johnson Innovation. » Full Release
// Lava Therapeutics Appoints Immuno-Oncology Experts James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., to Advisory Board Utrecht, The Netherlands and Philadelphia, Jan. 8, 2020 – Lava Therapeutics (“LAVA”) today announced that James P. Allison, Ph.D., a 2018 Nobel Prize recipient in Physiology or Medicine for his discovery of cancer therapy by inhibition of negative immune regulation, and Padmanee Sharma, M.D., Ph.D., a scientific leader in oncology, specializing in renal, bladder and prostate cancer, have joined the company’s Advisory Board. » Full Release
// Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform. Biologics Expert Paul Parren Joins as Head of R&D. ‘s Hertogenbosch, The Netherlands, 23 May 2018 – Lava Therapeutics (“LAVA”) today announced it has raised EUR 16 million in its first major institutional financing round from an investor syndicate led by Gilde Healthcare and Versant Ventures with additional support from US-based MRL Ventures Fund (MRLV), joining founder investors Lupus Ventures and Biox Biosciences. The funding will support development of LAVA’s proprietary pipeline of bispecific gamma-delta (γδ) T cell engagers for the treatment of cancer. LAVA also announced the appointment of Paul Parren, PhD, as Executive Vice President and Head of Research & Development. Dr. Parren joins the company as an internationally recognized antibody drug innovator and developer. » Full Release